10 years of IP work secures exclusive rights to use salmon roe technology from wound healing, psoriasis, atopical dermatitis to 3D bioprinting and skin diseases.

Most recent IP news!

Overview of patent portfolio (September 2020):

 

PATENTS UPDATE - GRANTING - FILING - NOTIFICATIONS

August 12th 2019

USPTO has today announced a notice of allowance of additional US patent on Regenics technology.

The patent is entitled: "CELLULAR EXTRACTS"

The U.S. Patent No. 16/011,134 is a continuation of U.S. Application No. 15/131,198 submitted  June 18 2018. Granting date by the USPTO is set at November 7th 2019. Patent expiration date is November 7th, 2039.

 

                                                     February 22th 2019

January 25th 2019

Additional Hong Kong patent filed ------ Filing of Hong Kong Patent Application No. 16104205.5 from Regenics on January 25th 2019. The Hong Kong patent application is based on EP Patent Application No. 13844535.8 Entitled: USE OF CELLULAR EXTRACTS FOR SKIN REJUVENATION. The granting is expected within 5 months from the filing date.  The application has been assigned serial number 16104205.5.    

 

December 19th 2018

EPO patent granted ------ Entitled: "COMPOSITION FOR USE IN WOUND HEALING "EPO No. 2656832 from EPO divisional patent application No. 1217881.5 Patent expiration dateis May 11th, 2027.

 

June 19th 2018

US patent granted ------ Entitled: "CELLULAR EXTRACTS"

U.S. Patent No.: U.S. Patent No. 9,999,639 granted from a

Continuation of U.S. Patent Application No. 15/131,198 filedon 18-Apr-2016. Patent expiration dateis September 8th, 2027.

 

 

August 19th 2018

EPO patent validated in Fr, UK, Ge, No, Swe, Da ------Entitled: "USE OF EGG CELLULAR EXTRACTS FOR SKIN REJUVENATION " for Regenics EPO patent No. 2928449 from Application No. 13844535.8Patent expiration dateis May 11th, 2027.

 

July 21st 2017

Japan patent granted ------ Entitled: "ADMINISTRATION OF CELLS AND CELLULAR EXTRACTS FOR REJUVENATION"

Japanese Patent No. 6177750 granted from Divisional of JP Patent Apllication No. 2009-508547. Patent expiration date is

 

June 28, 2016

Canadian national patent granted ------ Entitled: USE OF FISH EXTRACTS FOR REJUVENATION "

Canadian Patent no.: 2,798,137 granted from International Application no.: PCT/IB2011/001488. The patent expires May 5, 2031.

 

June 30th 2015

US patent granted ------ Entitled: "ADMINISTRATION OF CELLS AND CELLULAR EXTRACTS FOR REJUVENATION"

U.S. Patent No.: 9,066,883 granted from Application No: 13/909,372 filed 04-Jun-2013

 

 

 

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.